STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling
CONCLUSION: STMN1 silencing inhibits cell proliferation and BTZ resistance in MM by inactivating the PI3K/Akt signaling.PMID:37642368 | DOI:10.1080/14740338.2023.2251384 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 29, 2023 Category: Drugs & Pharmacology Authors: Ling Wang Jie Cao Yan Liang Jian Tao Source Type: research
Is the Psychedelic Experience an Essential Aspect of the Therapeutic Effect of Serotonergic Psychedelics? Conceptual, Discovery, Development and Implementation Implications for Psilocybin and Related Agents
Expert Opin Drug Saf. 2023 Aug 27. doi: 10.1080/14740338.2023.2253144. Online ahead of print.NO ABSTRACTPMID:37635320 | DOI:10.1080/14740338.2023.2253144 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 28, 2023 Category: Drugs & Pharmacology Authors: Roger S McIntyre Source Type: research
Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system
CONCLUSIONS: Treatment with joint therapy of ICIs and anti-VEGF agents may cause severe cutaneous adverse events. It is vital to identify ICI-related SCARs early, and to manage them appropriately.PMID:37622438 | DOI:10.1080/14740338.2023.2251381 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 25, 2023 Category: Drugs & Pharmacology Authors: Chunlei Li Zhengjun Li Qing Sun Yanxiao Xiang Anchang Liu Source Type: research
A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration adverse event reporting system data
CONCLUSION: The data mining of FAERS suggested an association between VTE and antipsychotic drugs, which reminds medical workers to pay attention to the serious adverse drug effects of antipsychotic drugs leading to venous thromboembolism.PMID:37615268 | DOI:10.1080/14740338.2023.2251881 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 24, 2023 Category: Drugs & Pharmacology Authors: Yu Yan Ling Wang Yanling Yuan Jiayue Xu Yuxian Chen Bin Wu Source Type: research
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study
CONCLUSION: Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.PMID:37608525 | DOI:10.1080/14740338.2023.2251398 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Xin Lai Qing Wan Shou-Feng Jiao Xiao-Chun Sun Jin-Fang Hu Hong-Wei Peng Source Type: research
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
CONCLUSIONS: Our study identified new AEs that have not been reported, which provides a new guidance to deepen the comprehension of the safety of Ubrogepant.PMID:37608560 | DOI:10.1080/14740338.2023.2251390 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Bing Cao Shanshan Gu Zhisen Shen Yuna Zhang Yiming Shen Hang Chen Source Type: research
Ocular adverse Events of cenegermin Used in neurotrophic Keratopathy: An Analysis of the FDA adverse event reporting system Database
CONCLUSION: This study revealed new cenegermin-related ocular AE signals. Clinical practice requires close monitoring to early identify and manage adverse reactions that may cause occurrence of serious irreversible consequences.PMID:37608598 | DOI:10.1080/14740338.2023.2251389 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Yunfei Li Haiyun Yang Yuan Gao Weimin He Source Type: research
Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)
CONCLUSIONS: This study highlights a number of AEs associated with selinexor. Most toxicities are reversible but require careful management. The benefit of selinexor still outweighs the potential risks, indicating XPO1 inhibitors as promising agents.PMID:37608630 | DOI:10.1080/14740338.2023.2248888 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Chenxin Chen Xiaoyong Miao Xiaojing Guo Jinfang Xu Jizhou Liang Yi Zheng Lijie Chi Xiao Chen Lianhui Wei Hewei Zhang Xiaofei Ye Jia He Source Type: research
Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance data
CONCLUSIONS: Our study suggested a safety signal for UTI and BTK inhibitors compared to all other drugs in the database, especially in the elder (age ≥60). Further studies are needed to clarify these results.PMID:37609933 | DOI:10.1080/14740338.2023.2251376 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Hui Yang Zhexin Ding Zhuoling An Source Type: research
Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA adverse Event Reporting System (FAERS)
CONCLUSION: Analysis of FAERS data identified anti-IL-5 mAbs-associated AEs, and our findings supported continuous clinical monitoring, pharmacovigilance, and further studies of anti-IL-5 mAbs. In addition, clinicians may be more aware of the limitations of use in package inserts of anti-IL-5 mAbs: Not for relief of acute bronchospasm or status asthmaticus. Because of some limitations in the FAERS such as self-reports from patients and other confounding factors, the safety of anti-IL-5 mAbs needed more studies in different dimensions, especially the risk of cancer.PMID:37610085 | DOI:10.1080/14740338.2023.2251382 (Source: ...
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Shu-Peng Zou Hai-Yun Yang Mengling Ouyang Qian Cheng Xuan Shi Ming-Hui Sun Source Type: research
An update on the safety of long-term vedolizumab use in inflammatory bowel disease
Expert Opin Drug Saf. 2023 Aug 23:1-10. doi: 10.1080/14740338.2023.2247976. Online ahead of print.ABSTRACTINTRODUCTION: Vedolizumab (Entyvio) is a humanized monoclonal antibody that disrupts the interaction between α4β7 integrin on circulating T-lymphocytes and MAdCAM-1 on the vascular endothelium to prevent their egress to sites of gut inflammation. It has proven therapeutic efficacy for the treatment of moderate-to-severe Crohn's disease, ulcerative colitis, and pouchitis.AREAS COVERED: This narrative review assesses the safety profile of vedolizumab from the registration trial programs, open-label extension studies, o...
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Sailish Honap Patrick Netter Silvio Danese Laurent Peyrin-Biroulet Source Type: research
